



(51) International Patent Classification:

C07D 231/40 (2006.01) C07D 413/14 (2006.01)
 C07D 401/12 (2006.01) C07D 417/12 (2006.01)
 C07D 401/14 (2006.01) C07D 417/14 (2006.01)
 C07D 403/12 (2006.01) C07D 471/04 (2006.01)
 C07D 403/14 (2006.01) C07D 487/04 (2006.01)
 C07D 405/12 (2006.01) C07D 513/04 (2006.01)
 C07D 405/14 (2006.01) A61K 31/415 (2006.01)
 C07D 413/12 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2020/050653

(22) International Filing Date:

28 January 2020 (28.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/799,455 31 January 2019 (31.01.2019) US
 62/959,042 09 January 2020 (09.01.2020) US

(71) Applicant: **PFIZER INC.**, [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors: **BEHENNA, Douglas Carl**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **FREEMAN-COOK, Kevin Daniel**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **HOFFMAN, Robert Louis**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **NAGATA, Asako**; c/

o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US). **NINKOVIC, Sacha**; c/o Pfizer Inc., 10777 Science Center, San Diego, CA 92121 (US). **SUTTON, Scott Channing**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.** et al.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: 3-CARBONYLAMINO-5-CYCLOPENTYL-1 FI-PYRAZOLE COMPOUNDS HAVING INHIBITORY ACTIVITY ON CDK2





FIG. 1



(57) Abstract: This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R^1 , R^2 and R^3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

10 September 2020 (10.09.2020)

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2020/050653

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D231/40 C07D401/12 C07D401/14 C07D403/12 C07D403/14
C07D405/12 C07D405/14 C07D413/12 C07D413/14 C07D417/12
C07D417/14 C07D471/04 C07D487/04 C07D513/04 A61K31/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2005/051919 A1 (PFIZER PROD INC [US]; BENBOW JOHN WILLIAM [US] ET AL.) 9 June 2005 (2005-06-09) claims; examples ----- -/-	1-20

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

1 April 2020

Date of mailing of the international search report

24/07/2020

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Stroeter, Thomas

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2020/050653

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MASCARENHAS N M ET AL: "An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation - A case study with CDK2/CyclinA", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 12, 1 December 2008 (2008-12-01), pages 2807-2818, XP025714726, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2007.10.016 [retrieved on 2007-10-22] table 1; compound 20 -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2020/050653

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005051919	A1	09-06-2005	
		AT 473967 T	15-07-2010
		BR PI0416989 A	06-02-2007
		CA 2547283 A1	09-06-2005
		DK 1689721 T3	20-09-2010
		EP 1689721 A1	16-08-2006
		ES 2347152 T3	26-10-2010
		JP 4864719 B2	01-02-2012
		JP 2007512315 A	17-05-2007
		US 2007276010 A1	29-11-2007
		WO 2005051919 A1	09-06-2005
